covid 19 immune globulin
Biologicalexperimental
Clinical trial activity
6 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
3
Phase 4
0
Earliest trial started Feb 17, 2020 (NCT04264858)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05142306 | Phase 1 | Dec 31, 2021 | Department of Defense, Emergent BioSolutions |
| NCT05173441 | Phase 2 | Dec 30, 2021 | Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, wuhan optics |
| NCT04891172 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2021 | Dow University of Health Sciences, Government of Pakistan |
| NCT04847141 | Phase 3 | Apr 28, 2021 | Grifols |
| NCT04842435 | Phase 2/Phase 3 (Phase 3) | Apr 12, 2021 | Microgen Scientific Industrial Company for Immunobiological Medicines |
| NCT04264858 | N/A | Feb 17, 2020 | Huazhong University of Science and Technology |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Tiantan Bio Co., Ltd | For profit | 1 | 0 | 1 | 2021 |
| China National Biotec Group Co., Ltd | For profit | 1 | 0 | 1 | 2021 |
| Department of Defense | Government | 1 | 0 | 1 | 2021 |
| Dow University of Health Sciences | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Emergent BioSolutions | For profit | 1 | 1 | 1 | 2021 |
| Government of Pakistan | Government | 1 | 0 | 1 | 2021 |
| Grifols | For profit | 1 | 1 | 1 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Microgen Scientific Industrial Company for Immunobiological Medicines | For profit | 1 | 1 | 1 | 2021 |
| wuhan optics | For profit | 1 | 1 | 1 | 2021 |
10 organizations
Page 1 / 1